Compound 9 was specifically developed as an agonist for PPAR beta/delta. Binding studies showed it also bound PPAR gamma. Because of the recent identification of PPAR beta/delta involvement in a number of cancers, we tested whether compound 9 would synergize with known chemotherapeutic agents to increase apoptosis in a human cancer cell line that expresses the PPAR beta/delta receptor. These studies revealed that compound 9 was capable of inducing apoptosis on its own, and did not synergize with doxorubicin in inducing apoptosis. We have undertaken a series of studies to determine if the apoptosis that compound 9 induces is being mediated through any of the PPAR receptors. We have also examined compound 9 ability to signal through the PPAR receptors in a variety of cell lines.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.